NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Fleeman N, Saborido CM, Payne K, et al. The Clinical Effectiveness and Cost-Effectiveness of Genotyping for CYP2D6 for the Management of Women with Breast Cancer Treated with Tamoxifen: A Systematic Review. Southampton (UK): NIHR Journals Library; 2011 Sep. (Health Technology Assessment, No. 15.33.)

Cover of The Clinical Effectiveness and Cost-Effectiveness of Genotyping for CYP2D6 for the Management of Women with Breast Cancer Treated with Tamoxifen: A Systematic Review

The Clinical Effectiveness and Cost-Effectiveness of Genotyping for CYP2D6 for the Management of Women with Breast Cancer Treated with Tamoxifen: A Systematic Review.

Show details

References

1.
Cancer Research UK. UK breast cancer – incidence statistics. 2010. URL: http://info​.cancerresearchuk​.org/cancerstats​/types/breast/incidence/ (cited 27 July 2010)
2.
Cancer Research UK. Breast cancer – UK mortality statistics. 2008. URL: http://info​.cancerresearchuk​.org/cancerstats​/types/breast/mortality/index.htm (cited 25 January 2010)
3.
National Institute for Health and Clinical Excellence (NICE). Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. London: NICE; 2006. Technology Appraisal TA112.
4.
Micheli A, Mugno E, Krogh V, Quinn MJ, Coleman M, Hakulinen T, et al. Cancer prevalence in European registry areas. Ann Oncol. 2002;13:840–65. [PubMed: 12123330]
5.
Cancer Research UK. Breast cancer – survival statistics. URL: http://info​.cancerresearchuk​.org/cancerstats​/types/breast/survival/ (cited 12 August 2011)
6.
Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(40) [PubMed: 17903394]
7.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71. [PubMed: 7545954]
8.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–92. [PubMed: 8524414]
9.
Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33–6. [PubMed: 11984562]
10.
The Endogenous Hormones Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–16. [PubMed: 11959894]
11.
Travis R, Key T. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003;5:239–47. [PMC free article: PMC314432] [PubMed: 12927032]
12.
Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389–99. [PubMed: 11705483]
13.
John EM, Phipps AI, Knight JA, Milne RL, Dite GS, Hopper JL, et al. Medical radiation exposure and breast cancer risk: Findings from the Breast Cancer Family Registry. Int J Cancer. 2007;121:386–94. [PubMed: 17372900]
14.
American Joint Committee on Cancer. AJCC cancer staging manual. 7th edn. Chicago: Springer; 2009.
15.
International Union Against Cancer. TNM classification of malignant tumours. 7th edn. New York: Wiley-Liss; 2009.
16.
Galea M, Blamey R, Elston C, Ellis I. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207–19. [PubMed: 1391987]
17.
Adjuvant! Online. URL: www​.adjuvantonline.com/index.jsp (cited 27 July 2010)
18.
National Institute for Health and Clinical Excellence. Early and locally advanced breast cancer: diagnosis and treatment. 2009. URL: www​.nice.org.uk/Guidance/CG80 (cited 11 March 2009) [PubMed: 19167201]
19.
Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol. 2003;86:255–63. [PubMed: 14623519]
20.
National Institute for Health and Clinical Excellence. Advanced breast cancer: diagnosis and treatment. 2009. URL: www​.nice.org.uk/Guidance/CG81 (cited 11 March 2009)
21.
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JGM, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–9. [PubMed: 12090977]
22.
Breast International Group 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57. [PubMed: 16382061]
23.
Jakesz R, Samonigg H, Greil R, Gnant M, Schmid M, Kwasny W, et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a) J Clin Oncol. 2005;23:S527.
24.
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–62. [PubMed: 16084253]
25.
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–70. [PubMed: 17307102]
26.
Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17:vii10–14. [PubMed: 16760270]
27.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71. [PubMed: 16145047]
28.
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18. [PubMed: 19949017]
29.
Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev. 2008;34:157–74. [PubMed: 18164821]
30.
Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26) [PubMed: 17610808]
31.
Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7:991–6. [PubMed: 17138220]
32.
Cuppone F, Bria E, Verma S, Pritchard KI, Gandhi S, Carlini P, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008;112:260–7. [PubMed: 18041059]
33.
Aiello EJ, Buist DS, Wagner EH, Tuzzio L, Greene SM, Lamerato LE, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008;107:397–403. [PubMed: 17393300]
34.
Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003;192:23–32. [PubMed: 14511900]
35.
US Food and Drug Administration. Sally's tamoxifen review. 2006. URL: www​.fda.gov/ohrms/dockets​/ac/06/briefing​/2006-4248B1-01-FDA-Tamoxifen​%20Background​%20Summary%20Final.pdf (cited 12 August 2011)
36.
Stebbing J, Stearns V, Davidson NE. Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics. 2007;8:1–3. [PubMed: 17187500]
37.
Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284–95. [PMC free article: PMC1712396] [PubMed: 9012401]
38.
Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40:58–66. [PubMed: 10631623]
39.
Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–43. [PubMed: 11972444]
40.
Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist. 2006;11:126–35. [PubMed: 16476833]
41.
Ramon YCT, Altes A, Pare L, Del Rio E, Alonso C, Barnadas A, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 2010;119:33–8. [PubMed: 19189210]
42.
US Food and Drug Administration. 510(k) Substantial equivalence determination decision summary. 2004. URL: www​.accessdata.fda.gov​/cdrh_docs/reviews/K043576.pdf (updated 19 April 2006; cited 21 April 2008)
43.
Roche Molecular Systems Inc.; US Food and Drug Administration. 510(k) Substantial Equivalence Determination Decision Summary for Roche AmpliChip CYP450 microarray for identifying CYP2D6 genotype (510(k) Number k042259). 2004. URL: www​.accessdata.fda.gov​/cdrh_docs/reviews/K042259.pdf (cited 12 August 2011)
44.
Li X, Quigg RJ, Zhou J, Gu W, Nagesh Rao P, Reed EF. Clinical utility of microarrays: current status, existing challenges and future outlook. Curr Genomics. 2008;9:466–74. [PMC free article: PMC2691672] [PubMed: 19506735]
45.
Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess. 2010;14(3) [PubMed: 20031087]
46.
Grossman I. Routine pharmacogenetic testing in clinical practice: dream or reality? Pharmacogenomics. 2007;8:1449–59. [PubMed: 17979518]
47.
Piper MA. CYP2D6 pharmacogenomics of tamoxifen treatment. Washington, DC: Blue Cross Blue Shield Association; 2008.
48.
Centre for Reviews and Dissemination (CRD). CRD's guidance for undertaking reviews in healthcare: systematic reviews. 3rd edn. York: CRD, University of York; 2008.
49.
Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758–64. [PubMed: 14652237]
50.
Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144:427–37. [PubMed: 16549855]
51.
Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues of concern. Stat Med. 2008;27:6547–69. [PubMed: 18837075]
52.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ. 2003;327:557–60. [PMC free article: PMC192859] [PubMed: 12958120]
53.
Little J, Higgins J. The HuGENet HUGE review handbook. 2006. Version 1.0. URL: www​.genesens.net/_intranet​/doc_nouvelles​/HuGE%20Review%20Handbook%20v11.pdf (cited 30 June 2008)
54.
Flockhart DA, O'Kane D, Williams MS, Watson MS, Gage B, Gandolfi R, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10:139–50. [PubMed: 18281922]
55.
Bijl M, van Schaik R, Lammers L, Hofman A, Vulto A, van Gelder T, et al. Confirmation of reduced breast cancer survival in CYP2D6 poor metabolizers on tamoxifen in a population-based cohort study. 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; National Harbor, MD. 18–21 March 2009; abstract no. PII-34.
56.
Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat. 2009;118:125–30. [PubMed: 19189212]
57.
Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White INH. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis. 2002;23:1897–901. [PubMed: 12419838]
58.
Burton A. Cytochrome genotype affects outcome with tamoxifen. Lancet Oncol. 2006;7:112.
59.
Chubak J, Buist DSM, Boudreau DM, Rossing MA, Lumley T, Weiss NS. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat. 2008;112:123–32. [PMC free article: PMC3519424] [PubMed: 18058227]
60.
Coller JK. Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. Clin Exp Pharmacol Physiol. 2003;30:845–8. [PubMed: 14678248]
61.
Connolly RM, Barron TI, Feely J, Kennedy MJ. Co-prescription rates of tamoxifen and CYP2D6 inhibitors: are we compromising breast cancer outcome?. 30th Annual San Antonio Breast Cancer Symposium; San Antonio, TX. 13–16 December 2007.
62.
Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EMJ. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: Formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002;30:869–74. [PubMed: 12124303]
63.
Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310:1062–75. [PubMed: 15159443]
64.
Dezentje VO, Nortier JWR, Guchelaar HJ, de Velde CJH, Gelderblom H. Clinical implications of CYP2D6 genotyping on tamoxifen treatment in breast cancer. 6th European Breast Cancer Conference; Berlin. 15–19 April 2008.
65.
Dieudonne AS, Lambrechts D, Claes B, Vandorpe T, Wildiers H, Timmerman D, et al. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users. Breast Cancer Res Treat. 2009;118:531–8. [PubMed: 19597703]
66.
Goetz MP, Suman V, Couch F, Ames M, Rae J, Erlander M, et al. An index based on HOXB13/IL17BR and CYP2D6 for determination of relapse and survival in tamoxifen-treated node negative breast cancer. Breast Cancer Res Treat. 2006;100:53.
67.
Goetz MP, Suman VJ, Couch F, Ames MM, Rae JM, Erlander MG, et al. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: Combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res. 2008;14:5864–8. [PMC free article: PMC2596658] [PubMed: 18794098]
68.
Grabinski JL, Smith LS, Chisholm GB, Drengler R, Rodriguez GI, Lang AS, et al. Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment. 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, GA. 2–6 June 2006.
69.
Irvin WJ Jr, Peppercorn JM, Dees EC, Lange L, Chiu WK, Evans JP, et al. The relationship between CYP2D6 genotype and endocrine symptoms in women taking tamoxifen. Breast Cancer Symposium, General Poster Session A; San Francisco, CA. 8–10 October 2009; abstract no. 238.
70.
Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85:151–9. [PubMed: 15111773]
71.
Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer. 2008;99:616–21. [PMC free article: PMC2527838] [PubMed: 18665165]
72.
Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006;318:503–12. [PubMed: 16690721]
73.
Lim HS, Lee HJ, Lee KS, Lee ES, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007;25:3837–45. [PubMed: 17761971]
74.
Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, et al. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008;108:421–6. [PMC free article: PMC2575100] [PubMed: 17541741]
75.
Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, et al. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther. 2008;83:702–10. [PMC free article: PMC2782693] [PubMed: 17713466]
76.
Ro J, Lim HS, Han HS. Clinical outcomes in correlation with pharmacokinetics and CYP2D6 genotypes in metastatic breast cancer patients on tamoxifen. Am J Hematol Oncol. 2008;7:65–7.
77.
Serrano D, Macis D, Gandini S, Johansson H, Guerrieri-Gonzaga A, Mellgren G, et al. Correlation of low dose tamoxifen and its metabolites plasma level with CYP 2D6, and SULT polymorphism; a pharmacogenetics study within a chemoprevention trial. J Clin Oncol. 2009;25:S503.
78.
Sridar C, Kent UM, Notley LM, Gillam EMJ, Hollenberg PF. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002;301:945–52. [PubMed: 12023523]
79.
Veenstra DL, Lin MP, Garrison LP, Burke W. An exploration of the potential clinical benefits and risks of CYP2D6 testing to guide tamoxifen therapy in breast cancer. Value Health. 2009;12:A4.
80.
Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009;69:1722–7. [PubMed: 19244106]
81.
Hawse JR, Wu X, Subramaniam M, Goetz P, Spelsberg TC, Ingle TC. Endoxifen, but not 4-hydroxytamoxifen, degrades the estrogen receptor in breast cancer cells: a differential mechanism of action potentially explaining CYP2D6 effect. 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX. 10–14 December 2008.
82.
Goetz MP, Berry DA, Klein TE., on behalf of the International Tamoxifen Pharmacogenomics Consortium (ITPC). Adjuvant tamoxifen treatment outcome according to Cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer. 32nd Annual San Antonio Breast Cancer Symposium; San Antonio, TX. 11 December 2009.
83.
Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113–21. [PubMed: 17115111]
84.
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312–18. [PubMed: 16361630]
85.
Gonzalez-Santiago S, Zarate R, de la Haba-Rodriguez J, Gomez A, Bandres E, Borrega P, et al. Genetic polymorphism CYP2D6(*4) interaction in clinical outcomes of tamoxifen-treated breast cancer patients. Ann Oncol. 2006;17:62–3.
86.
Gonzalez-Santiago S, Zárate R, Haba-Rodriguez J, Gomez A, Bandres E, Borrega P, et al. CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen. J Clin Oncol. 2007;25:S590.
87.
Henry NL, Nguyen A, Azzouz F, Li L, Robarge J, Philips S, et al. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer. 2009;102:294–300. [PMC free article: PMC2816645] [PubMed: 19953095]
88.
Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008;99:995–9. [PubMed: 18294285]
89.
Lim HS, Lee HJ, Lee KS, Lee ES, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX. 14–17 December 2006.
90.
Madlensky L, Flatt SW, Natarajan L, Lawrence HJ, Nikoloff DM, Fontecha M, et al. Hot flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen. 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX. 10-14 December 2008; Poster Session VI, abstract no. 6045.
91.
Newman WG, Hadfield KD, Latif A, Roberts SA, Shenton A, McHague C, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res. 2008;14:5913–18. [PubMed: 18794105]
92.
Nowell SA, Ahn JY, Rae JM, Scheys JO, Trovato A, Sweeney C, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005;91:249–58. [PubMed: 15952058]
93.
Okishiro M, Taguchi T, Kim SJ, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115:952–61. [PubMed: 19156902]
94.
Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA, et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat. 2009;115:643–50. [PubMed: 19082882]
95.
Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 2009;9:258–64. [PMC free article: PMC2991048] [PubMed: 19421167]
96.
Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25:5187–93. [PubMed: 18024866]
97.
Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No association between CYP2D6*10 genotype and survival of node-negative japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol. 2009;39:651–6. [PubMed: 19596663]
98.
Wang P, Lorizio W, Ziv E, Wu AHB. An analysis of the association between cytochrome P-450 2D6 polymorphism and incidence of adverse effects caused by tamoxifen in women with breast cancer. 42nd Annual Meeting of the Academy of Clinical Laboratory Physicians and Scientists; San Diego, CA. 7–9 June 2007.
99.
Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007;9:R7. [PMC free article: PMC1851378] [PubMed: 17244352]
100.
Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005;7:R284–90. [PMC free article: PMC1143572] [PubMed: 15987423]
101.
Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19:1423–9. [PubMed: 18407954]
102.
Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80:61–74. [PubMed: 16815318]
103.
Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, et al. Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX. 8–11 December 2005.
104.
Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol. 2007;19:56–61. [PubMed: 17947222]
105.
Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30–9. [PubMed: 15632378]
106.
Lim H, Lee H, Lee K, Lee E, Jang I, Ro J. CYP2D6 genotypes in association with steady state plasma concentrations of active metabolites of tamoxifen in patients with breast cancer. 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, GA. 2–6 June 2006.
107.
Henry LN, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, et al. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat. 2009;117:571–5. [PMC free article: PMC2746261] [PubMed: 19153830]
108.
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302:1429–36. [PMC free article: PMC3909953] [PubMed: 19809024]
109.
Thompson A, Quinlan P, Bray S, Johnson A, Nikoloff M, Fontecha M, et al. CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Symposium 2009; San Francisco, CA. 8–10 October.
110.
Goetz M, Suman V, Ames M, Black J, Safgren S, Kuffel M, et al. Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: long term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial. Cancer Res. 2009;69:6037.
111.
Quill T, Abair T, Garcia K, Peck S, Oshaughnessy JA. Benefit from adjuvant paclitaxel according to breast cancer subtype assessed by tissue microarrays. The American Society of Clinical Oncology. Breast Cancer Symposium 2009; San Francisco, CA. 8–10 October.
112.
Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, et al. Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. Clin Cancer Res. 2009;15:7053–60. [PubMed: 19887477]
113.
de Duenas EM, Ochoa E, Ferrer T, Ferrer C, Lisart R, Lopez A, et al. Tamoxifen pharmacogenetics of CYP2D6: effect of CYP2D6 genotype on tamoxifen metabolism and descriptive analysis of CYP2D6 variants in a Mediterranean population of early breast cancer patients. The American Society of Clinical Oncology. Breast Cancer Symposium 2009; San Francisco, CA. 8–10 October.
114.
Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28:1287–93. [PMC free article: PMC4872305] [PubMed: 20124171]
115.
Lorizio W, Beattie M, Tchu S, Melese T, Melisko M, Wu A, et al. Effect of CYP2D6 pharmacogenetic testing on selection of therapy. The American Society of Clinical Oncology. Breast Cancer Symposium 2009; San Francisco, CA. 8–10 October; abstract no. 144.
116.
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. 27th Annual San Antonio Breast Cancer Symposium; San Antonio, TX. 8–11 December 2004. [PubMed: 16361630]
117.
Ferraldeschi R, Newman WG. The impact of CYP2D6 genotyping on tamoxifen treatment. Pharmaceuticals. 2010;3:1122–38. [PMC free article: PMC4034025] [PubMed: 27713292]
118.
Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007;81:510–16. [PubMed: 17301735]
119.
Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008;100:642–8. [PMC free article: PMC2864146] [PubMed: 18445827]
120.
Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486–92. [PubMed: 17200148]
121.
Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res. 2010;6:4468–77. [PubMed: 20515869]
122.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802. [PubMed: 14551341]
123.
Delea TE, El-Ouagari K, Karnon J, Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008;108:375–87. [PubMed: 17653859]
124.
Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer. 2007;7:608–18. [PubMed: 17592673]
125.
El Ouagari K, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat. 2007;101:37–49. [PubMed: 16821085]
126.
Karnon J. Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness. Pharmacoeconomics. 2006;24:215–32. [PubMed: 16519544]
127.
Ferraldeschi R, Howell S, Thompson A, Newman W. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J Clin Oncol. 2010;28:e584–e585. [PubMed: 20823421]
128.
Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6. [PubMed: 12586795]
129.
McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99:1763–8. [PMC free article: PMC2600703] [PubMed: 18985046]
130.
Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–62. [PubMed: 18180462]
131.
Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000;2:E29. [PMC free article: PMC2761139] [PubMed: 11741245]
132.
Carlson B. First-in-class product seeks to promote better prescribing habits. Biotechnol Healthc. 2009;6:7–9. [PMC free article: PMC2799078] [PubMed: 22478758]
133.
Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28:3090–5. [PMC free article: PMC2903338] [PubMed: 20458026]
134.
Matloff ET, Moyer A, Shannon KM, Niendorf KB, Col NF. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making. J Womens Health (Larchmt) 2006;15:843–56. [PubMed: 16999640]
135.
Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing structural uncertainty in decision analytic models: a review and application of methods. London: Blackwell Publishing; 2009. pp. 739–49. [PubMed: 19508655]
136.
Dukek BA, O'Kane DJ. Comparison of Roche diagnostics AmpliChip CYP450IVD test with TM Bioscience Tag-It cytochrome P450 2D6 and 2C19 tests. Clin Chem. 2006;52:A52.
137.
Heller T, Kirchheiner J, Armstrong VW, Lathe H, Brockmoller J, Oellerich M. Assessment of Amplichip CYP450-based CYP2D6-genotyping and phenotype prediction compared to PCRRFLP- genotyping and phenotyping by metoprolol pharmacokinetics. Ther Drug Monit. 2005;27:221.
138.
Heller T, Kirchheiner J, Armstrong VW, Luthe H, Tzvetkov M, Brockmöller J, et al. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006;28:673–7. [PubMed: 17038884]
139.
Lawrence HJ, Truong S, Patten N, Nakao A, Wu L. Detection of p53 mutations in cancer by the amplichip p53 test, a microarray-based resequencing assay. The third international workshop on mutation p53; Lyons, France. November 2007.
140.
Melis R, Lyon E, McMillin GA. Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It mutation detection assays. Exp Rev Mol Diagn. 2006;6:811–20. [PubMed: 17140368]
141.
Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009;9:34–41. [PubMed: 18591960]
142.
Dezentje VO, Guchelaar HJ, Nortier JWR, van de Velde CJH, Gelderblom H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res. 2009;15:15–21. [PubMed: 19118028]
143.
Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med. 2006;144:397–406. [Summary for patients in Ann Intern Med 2006;144:I40, PMID 16549849.] [PubMed: 16549852]
144.
Annemans L. Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making. Pharmacoeconomics. 2008;26:409–23. [PubMed: 18429657]
145.
Armstrong K, Chen TM, Albert D, Randall TC, Schwartz JS. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol. 2001;98:996–1003. [PubMed: 11755544]
146.
Benedict A, Brown RE. Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer. Expert Opin Pharmacother. 2005;6:1789–801. [PubMed: 16144501]
147.
Preventive health program aims to reduce cost, incidence of breast cancer. Clin Resource Manag. 2001;2:26–9. [PubMed: 11246807]
148.
Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics. 2004;22:1153–65. [PubMed: 15612833]
149.
Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer. 2006;94:460–4. [PMC free article: PMC2361185] [PubMed: 16434989]
150.
Delea TE, Karnon J, Smith RE, Johnston SRD, Brandman J, Sung JCY, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care. 2006;12:374–86. [PubMed: 16834524]
151.
Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol. 2003;26:289–96. [PubMed: 12796603]
152.
Duelge J, Hillner TJ. Is tamoxifen cost-effective for prevention of breast cancer? J Clin Oncol. 2000;18:1807. [PubMed: 10764448]
153.
Dunn C, Keam SJ. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. Pharmacoeconomics. 2006;24:495–517. [PubMed: 16706574]
154.
Eckermann SD, Martin AJ, Stockler MR, Simes RJ. The benefits and costs of tamoxifen for breast cancer prevention. Aust NZ J Public Health. 2003;27:34–40. [PubMed: 14705265]
155.
Eisinger F. CYP2D6 and Ockham's razor. J Clin Oncol. 2008;26:686–7. [PubMed: 18235133]
156.
Gil JM, Rubio-Terres C, Del Castillo A, Gonzalez P, Canorea F. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin Transl Oncol. 2006;8:339–48. [PubMed: 16760009]
157.
Goeree R, Blackhouse G, Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin. 2006;22:1425–36. [PubMed: 16834841]
158.
Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol. 2002;20:9–16. [PubMed: 11773148]
159.
Higa GM. New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefits. Pharmacoeconomics. 2000;17:121–32. [PubMed: 10947336]
160.
Higa GM. Aromatase inhibitors for breast cancer: pharmacoeconomic considerations. Expert Opin Pharmacother. 2001;2:987–95. [PubMed: 11585014]
161.
Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer. 2001;91:484–9. [PubMed: 11169930]
162.
Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer. 2004;101:1311–22. [PubMed: 15368322]
163.
Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K. Economic evaluation of the prevention and treatment of breast cancer – present status and open issues. Breast Cancer. 2007;14:81–7. [PubMed: 17245000]
164.
Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int. 2005;16:15–25. [PubMed: 15672210]
165.
Karnon J, Jones T. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. Pharmacoeconomics. 2003;21:513–25. [PubMed: 12696991]
166.
Karnon J, Johnston SRD, Jones T, Glendenning A. A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann Oncol. 2003;14:1629–33. [PubMed: 14581270]
167.
Karnon J, Delea T, Johnston SRD, Smith R, Brandman J, Sung J, et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics. 2006;24:237–50. [PubMed: 16519546]
168.
Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ. 2008;9:171–83. [PubMed: 17602251]
169.
Keyzer JF, Melnikow J, Kuppermann M, Birch S, Kuenneth C, Nuovo J, et al. Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview. Ethn Dis. 2005;15:395–406. [PubMed: 16108298]
170.
Kellokumpu-Lehtinen P, Bergh J, Salminen E, Wiklund T, Lehtinen S, Aronen P, et al. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy: results from a randomized study. Acta Oncol. 2007;46:146–52. [PubMed: 17453362]
171.
Kilian R, Porzsolt F. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature. Breast. 2005;14:636–42. [PubMed: 16183288]
172.
Lindgren P, Jonsson B, Redaelli A, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics. 2002;20:101–8. [PubMed: 11888362]
173.
Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007;106:229–38. [PubMed: 17245540]
174.
Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol. 2006;17:217–25. [PubMed: 16267126]
175.
Lundkvist J, Wilking N, Holmberg S, Jonsson L. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat. 2007;102:289–99. [PubMed: 17033927]
176.
Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial. Br J Cancer. 2007;97:152–61. [PMC free article: PMC2360294] [PubMed: 17622238]
177.
Marchetti M, Caruggi M, Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin Ther. 2004;26:1546–61. [PubMed: 15531017]
178.
Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health. 2007;7:6. [PMC free article: PMC1866224] [PubMed: 17439652]
179.
Melnikow J, Birch S, Slee C, McCarthy TJ, Helms LJ, Kuppermann M. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis. Med Care. 2008;46:946–53. [PubMed: 18725849]
180.
Miller LAN, Roy A, Mody R, Higa GM. Comparative economic analysis of aromatase inhibitors and tamoxifen in the treatment of hormone-dependent breast cancer. Expert Opin Pharmacother. 2007;8:1675–91. [PubMed: 17685885]
181.
Moeremans K, Annemans L. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int J Gyn Cancer. 2006;16:S576–8. [PubMed: 17010076]
182.
Mullins CD, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm. 2003;9:150–8. [PubMed: 14613344]
183.
Naeim A, Keeler EB. Is adjuvant therapy for older patients with node(−) early breast cancer cost-effective? Crit Rev Oncol Hemat. 2005;53:81–9. [PubMed: 15607936]
184.
National Institute for Health and Clinical Excellence. Breast cancer (early): hormonal treatments: costing template and report. 2006. http://guidance​.nice​.org.uk/TA112/CostingReport/xls/English (cited 12 August 2011)
185.
Okubo I, Kondo M, Toi M, Ochiai T, Miki S. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. Jpn J Cancer Chemo. 2005;32:351–63. [PubMed: 15791818]
186.
Ozanne EM, Esserman LJ. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev. 2004;13:2043–52. [PubMed: 15598759]
187.
Risebrough NA, Verma S, Trudeau M, Mittmann N. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer. 2007;110:499–508. [PubMed: 17592825]
188.
Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer. 2006;14:917–27. [PubMed: 16596419]
189.
Rodriguez-Antona C, Gurwitz D, de Leon J, Llerena A, Kirchheiner J, de Mesa EG, et al. CYP2D6 genotyping for psychiatric patients treated with risperidone: Considerations for cost-effectiveness studies. Pharmacogenomics. 2009;10:685–99. [PubMed: 19374522]
190.
Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys. 2009;74:440–6. [PMC free article: PMC2695677] [PubMed: 18963542]
191.
Simons WR, Jones D, Buzdar A. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther. 2003;25:2972–87. [PubMed: 14693319]
192.
Skedgel C, Rayson D, Dewar R, Younis T. Cost–utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen–exemestane and upfront anastrozole. Breast Cancer Res Treat. 2007;101:325–33. [PubMed: 16897433]
193.
Skedgel C, Rayson D, Dewar R, Younis T. Cost–utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen–exemestane and extended tamoxifen–letrozole. Breast. 2007;16:252–61. [PubMed: 17207623]
194.
Smith TJ, Hillner BE. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol. 2000;18:284–6. [PubMed: 10637241]
195.
Thompson D, Taylor DCA, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health. 2007;10:367–76. [PubMed: 17888101]
196.
Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess. 2006;10(34) [PubMed: 16959170]
197.
Younis T, Rayson D, Dewar R, Skedgel C. Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. Ann Oncol. 2007;18:293–8. [PubMed: 17095569]
198.
Irvin WJ, Carey LA, Olajide O, Dees EC, Peppercorn J, Chiu WK, et al. Comprehensive CYP2D6 genotyping in a multiracial U.S. breast cancer population. J Clin Oncol. 2009;27 abstract 553.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK99697

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (988K)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...